Journal article

IPH4102, a monoclonal antibody directed against the immune receptor molecule KIR3DL2, for the treatment of cutaneous T-cell lymphoma

Carrie Van Der Weyden, Martine Bagot, Paul Neeson, Phil K Darcy, H Miles Prince

Expert Opinion on Investigational Drugs | TAYLOR & FRANCIS LTD | Published : 2018

DOI: 10.1080/13543784.2018.1498081

Citation metrics

5Web of Science
5Scopus

Keywords

Anti-Ccr4 Antibody
Humans
Phase-Ii
Prognostic-Factors
Receptors, Kir3dl2
Science & Technology
Sezary-Syndrome
Natural-Killer
Mycosis Fungoides
Monoclonal Antibody
Antibodies, Monoclonal
Kir3dl2
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Mycosis-Fungoides
Alemtuzumab
Sézary Syndrome
International-Society
Recommendations
Iph4102
Brentuximab Vedotin
Lymphoma, T-Cell, Cutaneous
Antineoplastic Agents
Sezary Syndrome
Animals
Cutaneous T-Cell Lymphoma